Parexel, a leading global clinical development partner, has acquired Vitrana, a provider of an AI-enabled, end-to-end pharmacovigilance technology platform. Financial terms were not disclosed. The acquisition expands Parexel’s technology capabilities, providing an integrated platform that leverages intelligent automation and AI to accelerate patient safety and pharmacovigilance processes, deliver first-time quality, and enhance compliance.
Vitrana’s platform is system-agnostic and integrates with any safety database, allowing customers to deploy capabilities that best fit their needs while improving accuracy, cycle times, and operational efficiency. The acquisition means Parexel can now offer customers a single partner for both pharmacovigilance technology and services. The Vitrana team and technology will be aligned with Parexel’s Patient Safety Services organization, with the business operating as Vitrana, a Parexel Company during the transition.
KEY QUOTES:
“With Vitrana, we can now offer customers a single partner for both PV technology and services, and that changes what we can deliver for them. Our customers will benefit from best-in-class, technology-enabled PV services that handle growing regulatory volume and complexity, enhance compliance, streamline workflows, and enable experts to focus on what matters most: product and patient safety.”
Sanjay Vyas, President of Patient Safety Services and Clinical Logistics, Parexel
“We’re thrilled to join Parexel and further scale our proven technology and our experienced team as we strengthen pharmacovigilance solutions. Together, we can offer improved efficiency, quality and compliance for our customers worldwide.”
Mohit Gupta, President and CEO, Vitrana
